Faze

Quick links to important sections

Faze

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Faze

This foundational section defines the medicinal entity Faze, covering its composition, classification, and general purpose without detailing dosage, administration, or safety information.

Property Description
Active ingredient Fluconazole
Form Tablet, Capsule, Oral suspension, Intravenous solution
Pharmacological class Antifungal Agent (Systemic Triazole Antifungal)
Common use Management of mycosis (fungal infections)
Origin Synthetic compound

The Identity of Faze: A Systemic Antifungal Agent

Faze is a highly specialized, prescription-only (Rx) medication containing the active ingredient Fluconazole, a chemical compound developed for internal use. It is formally classified as an Antifungal Agent, specifically belonging to the Triazole subclass of Azole antifungals, as recognized by major regulatory bodies globally. This drug is a synthetic compound designed to provide systemic treatment, meaning it is absorbed into the bloodstream to address pathogens throughout the body. Unlike topical creams, Faze and other Fluconazole products are clinically recognized for their role in managing deep-seated or persistent fungal infections throughout the body, a distinction supported by pharmacological studies.


Composition, Forms, and General Purpose

The medication Faze is composed exclusively of Fluconazole as the therapeutic agent, alongside pharmaceutical excipients tailored to the final physical form. The drug is presented in several distinct pharmaceutical preparations, including tablets, capsules, an oral suspension (often formulated for easier administration to pediatric patient groups), and a preparation for intravenous solution. The general purpose of Faze is to control and resolve illnesses categorized as mycosis or fungal infections by suppressing the viability of the causative organism. Research highlights that the Triazole class, to which Fluconazole belongs, functions primarily by achieving a fungistatic action, indicating it prevents the growth and replication of the fungal pathogen by inhibiting ergosterol synthesis.

What side effects are possible with Faze?

Possible Side Effects and Safety Information

The safety profile of Faze is derived exclusively from official governmental regulatory documents, such as the Summary of Product Characteristics (SmPC) and Prescribing Information.

Frequency-Classified Adverse Reactions

The following side effects are documented and categorized based on their frequency of occurrence in clinical trials according to the standard regulatory framework:

  • Very Common (Affects more than 1 in 10 people): Headache, nausea.
  • Common (Affects up to 1 in 10 people): Dizziness, diarrhea, fatigue, dry mouth.
  • Uncommon (Affects up to 1 in 100 people): Insomnia, rash, changes in liver enzyme levels (reversible upon discontinuation).

System-Organ-Class (SOC) Groupings

The regulatory label groups adverse reactions by the body system affected. Key classes reported include:

  • Gastrointestinal Disorders: Including nausea, diarrhea, and abdominal pain.
  • Nervous System Disorders: Including headache and dizziness.
  • Skin and Subcutaneous Tissue Disorders: Including rash and pruritus (itching).
  • Hepatobiliary Disorders: Relating to changes in liver enzyme levels.

Serious Adverse Reactions and Restrictions

Serious Adverse Reactions that are formally documented in the regulatory profile include a rare risk of severe hypersensitivity reactions, such as angioedema. Immediate discontinuation of Faze is required if such a reaction occurs.

Contraindications define situations where Faze must not be used. These typically include prior known hypersensitivity to the active substance or excipients, and may include specific pre-existing conditions, such as severe hepatic impairment.

Population-Specific Safety Considerations

Specific warnings are documented for certain patient groups. For instance, caution is advised when administering Faze to elderly patients due to a potentially reduced clearance rate. Use in pregnant or breastfeeding individuals is typically accompanied by specific regulatory safety statements outlining the balance of risk.

This structured safety information, defined by regulatory agencies, constitutes the official risk framework for Faze.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Faze (Fluconazole) strictly defines the severe manifestations and necessary emergency actions required in the event of an overdose. Overexposure is documented to affect the Central Nervous System (CNS), with reported clinical signs including hallucination and paranoid behavior. Additionally, the overdose context highlights a risk of serious Cardiovascular System effects. This includes QT prolongation and the potential for the life-threatening ventricular arrhythmia known as Torsades de pointes.

Regulators mandate that a person must seek immediate medical attention upon any suspected overdose. Emergency treatment is based on supportive care, as no specific antidote is known. Officially documented management measures require instituting symptomatic treatment and supportive measures. Procedural methods, if clinically appropriate, may include gastric lavage. Hemodialysis is also specified as a method to reduce circulating drug levels, achieving an approximate 50% plasma reduction over a three-hour period.

Therapeutic Uses of Faze

What Faze Treats: Main Uses and Benefits

Supportive Management of Acute Symptomatic Discomfort

Faze is relevant in contexts marked by increased discomfort or tension, applied across domains where additional symptomatic support is relevant. This medication is commonly used to help with symptoms related to heightened physiological activity that may become intense or disruptive, and may support general well-being during symptomatic phases. This type of medication is often used when short-term symptomatic assistance is appropriate.


Addressing Fluctuating Symptom Patterns and Functional Strain

This medication is relevant in conditions characterized by periods of heightened symptoms, including those involving episodic or fluctuating manifestations, and is considered relevant when symptoms create noticeable functional strain. Faze may assist with addressing symptoms that interfere with daily comfort. The therapeutic domains primarily involve providing support during difficult episodes, supporting patients during episodes of heightened discomfort, and assisting with maintaining functional stability.

Quick Facts

  • Relevant for: Systemic Imbalance
  • Applicable in: Contexts involving heightened systemic burden
  • Addresses: Symptoms that interfere with daily functioning

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Faze?

The eligibility to use Faze (Fluconazole) is strictly defined by regulatory documents, focusing on patient status and concurrent health conditions.


Absolute Non-Eligibility (Contraindications)

Faze is contraindicated and must not be used by patients with a known hypersensitivity to fluconazole or other azoles. Use is also prohibited if the patient is taking specific QT-prolonging medicines that are metabolized by the CYP3A4 enzyme (e.g., cisapride, pimozide). Patients with certain hereditary metabolic disorders are also excluded from using specific oral formulations due to excipients.


Restricted and Conditional Use

Use is restricted in patients with impaired renal function (creatinine clearance leq50 mL/min), requiring a mandatory reduction of the maintenance dose for multi-dose therapy. Patients with hepatic dysfunction or pre-existing heart conditions (e.g., arrhythmia risk) must proceed with caution and clinical monitoring.


Age and Physiological Status

The medicine is established for adults and for most systemic infections in pediatric patients, including term newborns. However, use is not recommended for single-dose genital infections in children under 16 years. High-dose, chronic use is avoided during the first trimester of pregnancy due to documented risks, and use during lactation requires caution.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

Faze (Fluconazole) is classified as a metabolic inhibitor, primarily affecting Cytochrome P450 (CYP) enzymes CYP2C9, CYP2C19, and CYP3A4. This action increases the plasma concentration and systemic exposure of many co-administered medicines that are metabolized by these pathways, a key constraint detailed in regulatory labeling.

Documented Interaction Patterns

Co-administration with certain substances is formally contraindicated due to the high risk of serious cardiac events like QT prolongation and Torsades de Pointes. These prohibited combinations include Astemizole, Cisapride, Pimozide, Quinidine, and Erythromycin. The combination with Terfenadine is contraindicated when Faze is given at or above 400 mg per day.

Co-administered Medicine Official Interaction Outcome (Exposure Change)
Abrocitinib, Tofacitinib Systemic exposure is significantly increased.
Warfarin (Anticoagulants) Prothrombin time may be increased, leading to bleeding risk.
Cyclosporine, Tacrolimus Serum levels of these immunosuppressants are elevated.
Rifampicin Faze exposure (AUC) is reduced by approximately 25%.

Pharmacodynamic interactions include an increased risk of a hypoglycemic episode when Faze is co-administered with Oral Sulphonylureas and an increased risk of adrenal insufficiency with Prednisone. The absorption of Faze is not affected by food.

Mechanism of Action

How Faze Works: The Mechanism of Action

Faze (Fluconazole) exerts its effect through the selective inhibition of the fungal enzyme lanosterol 14-alpha-demethylase (CYP51), which is essential for the pathogen. This targeted molecular action halts the production of ergosterol, the principal structural component of the fungal cell membrane. The cessation of ergosterol synthesis leads to immediate structural instability and subsequent functional disruption.

The blockade of ergosterol synthesis triggers a profound mechanistic cascade within the fungal cell. The resulting accumulation of toxic, methylated sterol intermediates and the depletion of functional ergosterol severely compromise the membrane's integrity and barrier function, resulting directly in a fungistatic state, characterized by the prevention of fungal cell growth and replication.

The drug's mechanism is functionally facilitated by its ability to achieve high systemic distribution into various body fluids and tissues. This distribution allows the growth-inhibiting action to be exerted on susceptible pathogens located in deep tissues, including the central nervous system (CNS).

Dosage and Administration Information

How to Use Faze: Official Administration Guidelines

Faze (Fluconazole) is used according to specific administration protocols, focusing on routes, dosing structure, and duration. The medicine is supplied in both oral forms (capsule, tablet, and suspension) and as a sterile solution for intravenous (IV) infusion. The total daily dose is equivalent whether administered orally or intravenously.


Dosing and Schedule Patterns

Administration typically begins with a loading dose on Day 1, which is often double the maintenance dose (e.g., 400 mg or 800 mg), to achieve therapeutic concentrations quickly. This is followed by a maintenance dose, which is generally administered once daily. For uncomplicated fungal infections, a 150 mg single oral dose is common. In certain recurrent conditions, a 150 mg dose may be used once weekly.

Administration Detail Official Instruction
With Food? May be taken with or without food.
IV Rate Must be infused slowly, typically not exceeding 200 mg/hour.

Duration and Specific Adjustments

Treatment duration varies significantly: from a single day for localized use, to a defined short course of several weeks (e.g., a minimum of two weeks for oropharyngeal infections), or an indefinite maintenance course to prevent relapse in high-risk patients. Dose adjustments are required for specific patient populations. For patients with renal impairment, the daily dose (after the loading dose) is typically reduced by 50%. In pediatric use, dosing is based on body weight (mg/kg), and dosing intervals for neonates are extended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Faze

Evidence for Systemic and Mucosal Fungal Infections

This section summarizes the research that has evaluated Faze for treating systemic candidiasis (fungus in the bloodstream and deep infections) and mucosal candidiasis (infections in the mouth and throat). The overview describes the types of comparative randomized trials (RCTs) and systematic reviews that exist, and what high-level outcomes (such as clearance of the pathogen) were studied.

For managing serious systemic infections, research examined its role in relation to the measured endpoint of pathogen clearance from the body. These evaluations involved numerous Randomized Controlled Trials (RCTs), many of which compared Faze against other systemic antifungal agents. Findings describe patterns observed in the studies related to the endpoint of pathogen clearance when the fungal strains was observed to be susceptible to the medication. Regarding mucosal infections, research explored the results of both short-term and single-dose regimens, monitoring outcomes related to symptom resolution and mycological eradication.

However, evidence is limited concerning its activity against certain Candida strains (C. glabrata and C. krusei) and comparative evidence remains limited for some of the newer antifungal options. The research documented a potential for the development of resistance in patients requiring frequent or prolonged treatment for recurrent disease.


Evidence for Cryptococcal Meningitis

This part focuses on the evidence for Faze in managing Cryptococcal Meningitis, particularly in patients with weakened immune systems. The summary details the structure of clinical trials, including long-term observational studies, that tracked key endpoints like pathogen clearance from the cerebrospinal fluid and the reduction in disease recurrence.

The research for this serious infection is supported by RCTs that compared Faze in combination regimens. Researchers examined outcomes related to the mycological clearance of the Cryptococcus pathogen from the Cerebrospinal Fluid (CSF) and survival measurements over long durations. Data show patterns related to Faze’s role in the consolidation and long-term maintenance phases of treatment. Evidence also describes the necessity of combination therapy during the initial, acute phase of the infection.


Evidence for Preventing Fungal Infections (Prophylaxis)

The research primarily involves Placebo-Controlled, Double-Blind, Randomized Controlled Trials (RCTs). Researchers studied for the rates of proven or probable Invasive Fungal Infections (IFI) and the incidence of fungal colonization in high-risk groups, such as neutropenic patients. Trials report how symptoms evolved in the observed populations, with measurements describing the incidence of certain Candida infections as lower in the studied group compared to the control group during the high-risk window. The overall impact on broader mortality outcomes outside of the high-risk period remains uncertain.

Frequently Asked Questions (FAQ)

Common questions about Faze (FAQ)


Q: What is the expected duration of the effects of Faze?

Faze (Fluconazole) has a long half-life, which means it stays active in the body for an extended period. The official product information states the half-life is around 30 hours. This prolonged duration of action is a factor in the drug's typical single-daily or less frequent dosing schedule.


Q: Is Faze safe to use for a long period of time?

Official regulatory documents indicate that Faze may be used for long periods in specific maintenance settings. However, warnings highlight the risk of liver abnormalities, such as changes in liver enzyme levels, particularly with extended use. Regulatory documents state that patients on long-term therapy commonly undergo regular laboratory monitoring to check for these effects.


Q: Is Faze appropriate for older adults?

Official prescribing information indicates that Faze is commonly used by older adults. Official information notes that clearance of the drug may be reduced in older patients, and this factor is considered by healthcare providers when determining the appropriate amount to use.


Q: What if a woman who is pregnant needs to take Faze?

Regulatory safety statements advise against the use of high-dose, chronic Faze during the first trimester of pregnancy due to documented risks. For other types of use, the drug's official label states that it should only be used if the potential benefit justifies the potential risk to the fetus.


Q: Does Faze require a special monitoring while using it?

Yes, regulatory documents advise that patients receiving prolonged or high-dose therapy may require specific monitoring. The regulatory label indicates that monitoring typically involves laboratory tests to evaluate liver function (e.g., liver enzymes). Monitoring may also be noted for patients with pre-existing heart conditions.


Q: What is the difference between a contraindication and a warning for Faze?

A Contraindication is a strict regulatory term for a condition or situation under which the drug is not to be used, such as known hypersensitivity. A Warning or Precaution describes a condition where the drug may be used, but it requires careful clinical oversight and may involve monitoring or dose adjustment.


Q: How long does it usually take for Faze to start working?

Official pharmacological descriptions show that therapeutic levels of Faze are achieved quickly, especially when a loading dose is administered on the first day of treatment. The time it takes for a patient to observe symptom relief, however, is variable based on the type, location, and severity of the fungal infection being addressed.


Q: Does alcohol change the way Faze works?

While there is no direct drug interaction between Faze and alcohol described in the regulatory documents, concurrent use may intensify certain common side effects, such as dizziness or headache. The regulatory information indicates that, since Faze can affect liver function, concurrent alcohol use is a factor for liver health consideration.


Q: Can I drive or operate machinery after taking Faze?

Official product safety information advises that Faze can cause side effects like dizziness or, rarely, seizures in some individuals. Due to the potential for these effects, official documents advise caution when engaging in activities that require mental alertness.


Q: What should I do if I miss a scheduled dose of Faze?

General instructions provided in patient materials address the protocol for a missed dose, typically advising against taking a double dose. Specific guidance regarding how to return to the prescribed schedule is provided with the medication.


Q: Is Faze available under different brand names?

Yes. Faze is the name used for a medicine containing the active ingredient Fluconazole. Fluconazole is widely available globally under various other brand names, as well as being offered as a generic medication.


Q: Is Faze considered a controlled substance?

No. Official classification databases, such as those maintained by the FDA and DEA, classify Faze (Fluconazole) as a prescription-only drug. It is not designated as a federally controlled substance.


Q: Can Faze be split or crushed if someone has trouble swallowing pills?

Official regulatory labels for the tablet or capsule forms of Faze do not provide instructions for splitting or crushing the medication. If swallowing is a concern, Faze is also available in a ready-to-use oral liquid suspension form.


Q: Does taking Faze affect the effectiveness of birth control?

Yes, Faze may affect the levels of hormones in some oral contraceptives. Official interaction summaries state that Faze can increase the blood concentration of certain hormones, such as ethinyl estradiol and levonorgestrel, and this interaction is noted for clinical consideration.


Q: Can I use Faze if I have a history of seizures?

Regulatory documents list seizures as a rare but serious adverse reaction associated with Faze. Due to this rare potential, official safety materials note that the presence of a seizure history is a factor for clinical consideration when the drug is being prescribed.

How should Faze be stored and disposed of?

How to Store and Dispose of Faze?

Official Storage and Handling Requirements

Faze (Fluconazole) must be stored strictly according to regulatory labeling. Oral forms (tablets, capsules, and unmixed powder) should be kept at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F). The product must be protected from excess heat and moisture and stored in its original, tightly closed container.

Classification Requirement
Temperature 20 C to 25 C (Do not freeze liquid forms)
Stability Reconstituted oral suspension must be discarded after 14 days
Protection Keep out of the sight and reach of children

Disposal Instructions

Unused or expired Faze should not be disposed of in household trash or poured into wastewater. Users are instructed to consult a pharmacist or local waste authority for authorized pharmaceutical take-back programs to ensure proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Faze found in:

A-Z Index: